THURSDAY, JUNE 20, 2013
The Increasing Sophistication of Cyber Threats:
Protecting Your IP and Your Deal
It is far easier to steal valuable intellectual property than to create it from scratch. What most companies don’t know is that firewalls and other standard security measures are no match for today’s cyber thieves, who are often recruited, housed and protected by nation states solely for their cyber-thieving skills.
This month's panel will identify common threats and discuss best practices
to better protect your company’s information assets.
Where: Holiday Inn North Campus,
3600 Plymouth Road at US-23, Ann Arbor, MI
When: Thursday, June 20, 2013
Registration and networking 5:00 p.m., program begins at 5:45
Cost: Free to NEF members, $20 for non-members, $5 for students.
Program Partners: A2Y Regional Chamber
Great Lakes Entrepreneurs Quest
Presenters May 2012
SPINN (White Pines LLC)
The Companyís biggest customer, Centerstone, is seeing significant quantifiable results in improved operating efficiency and outcomes using SPINNís technology. Centerstone is the largest non-profit community behavioral healthcare provider in the nation. The improvement is receiving national attention: Centerstone was a presenter two weeks ago at the annual conference of the National Council of Community Behavioral Healthcare and featured the SPINN solution.
The Company successfully built a 63mm, 175w motor for Borg Warner, meeting all required metrics. They also have a new customer that is planning to use the motor for an industrial application. Lektromotive is not presently pursuing VC monies, choosing instead to internally finance their development.
Other NEF Entrepreneurs in the News
Aastrom Biosciences Inc. (Presenter 1993) has named Dominick C. Colangelo as President/CEO of the firm. Colangelo will also sit on the Board. He was most recently with Eli Lilly and Company, and has held executive positions of increasing responsibility in product development, pharmaceutical operations, sales/marketing, and corporate development. He also has experience in the acquisition, development, and commercialization of disease therapies.
Aastrom is a leading developer of patient-specific, expanded multicellular therapies for the treatment of cardiovascular diseases. To learn more, visit http://www.aastrom.com/
Tuesday, May 14, 2013